Gold nanoparticle enhancement of stereotactic radiosurgery for neovascular age-related macular degeneration

Physics in Medicine and Biology

Volumn 57, Issue 20, 2012, Pages 6371-6380

  Ngwa, Wilfred ^a   Makrigiorgos, G Mike ^a   Berbeco, Ross I ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGE-RELATED MACULAR DEGENERATION; CONCENTRATION RANGES; DEVELOPED COUNTRIES; GOLD NANOPARTICLE; GOLD NANOPARTICLES; MICRO-DOSIMETRY; RADIOSENSITIZERS; STEREOTACTIC RADIOSURGERY; SUB-CELLULAR; THERAPEUTIC EFFICACY; X RAY BEAM;

DOSIMETRY; GOLD; METAL NANOPARTICLES; OPHTHALMOLOGY; RADIOTHERAPY; X RAYS;

ENDOTHELIAL CELLS;

GOLD; METAL NANOPARTICLE; RADIOSENSITIZING AGENT;

ARTICLE; CHEMISTRY; FEASIBILITY STUDY; HUMAN; METHODOLOGY; NEOVASCULARIZATION (PATHOLOGY); PATHOPHYSIOLOGY; RADIOMETRY; RADIOSURGERY; RETINA MACULA DEGENERATION;

FEASIBILITY STUDIES; GOLD; HUMANS; MACULAR DEGENERATION; METAL NANOPARTICLES; NEOVASCULARIZATION, PATHOLOGIC; RADIATION-SENSITIZING AGENTS; RADIOMETRY; RADIOSURGERY;

EID: 84867240360     PISSN: 00319155     EISSN: 13616560     Source Type: Journal    
DOI: 10.1088/0031-9155/57/20/6371     Document Type: Article

References (46)

1. AMD Alliance International 2010 The Global Economic Cost of Visual Impairment (Sydney: Access Economics)
2. Axer-Siegel R, Ehrlich R, Yassur Y, Rosenblatt I, Kramer M, Priel E, Benjamini Y and Weinberger D 2004 Photodynamic therapy for age-related macular degeneration in a clinical setting: visual results and angiographic patterns Am. J. Ophthalmol. 137 258-64 (Pubitemid 38220997)
3. Bakri S J, Pulido J S, Mukherjee P, Marler R J and Mukhopadhyay D 2008 Absence of histologic retinal toxicity of intravitreal nanogold in a rabbit model Retina 28 147-9
4. Bonnaud S, Niaudet C, Pottier G, Gaugler M H, Millour J, Barbet J, Sabatier L and Paris F 2007 Sphingosine-1-phosphate protects proliferating endothelial cells from ceramide-induced apoptosis but not from DNA damage-induced mitotic death Cancer Res. 67 1803-11 (Pubitemid 46389242)
5. Bressler N M 2009 Antiangiogenic approaches to age-related macular degeneration today Ophthalmology 116 S15-23
6. Brown D M, Kaiser P K, Michels M, Soubrane G, Heier J S, Kim R Y, Sy J P and Schneider S 2006 Ranibizumab versus verteporfin for neovascular age-related macular degeneration New Engl. J. Med. 355 1432-44 (Pubitemid 44511558)
7. Brown D M, Michels M, Kaiser P K, Heier J S, Sy J P and Ianchulev T 2009 Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study Ophthalmology 116 57-65 e5
8. Canton V M, Quiroz-Mercado H, Velez-Montoya R, Lopez-Miranda M J, Moshfeghi A A, Shusterman E M, Kaiser P K, Sanislo S R, Gertner M and Moshfeghi D M 2011 16-Gy low-voltage x-ray irradiation with ranibizumab therapy for AMD: 6-month safety and functional outcomes Ophthalmic Surg. Lasers Imaging 42 468-73
9. Canton V M, Quiroz-Mercado H, Velez-Montoya R, Lopez-Miranda M J, Moshfeghi A A, Shusterman E M, Kaiser P K, Sanislo S R, Gertner M and Moshfeghi D M 2012 24-Gy low-voltage x-ray irradiation with ranibizumab therapy for neovascular AMD: 6-month safety and functional outcomes Ophthalmic Surg. Lasers Imaging 43 20-4
10. Cole A 1969 Absorption of 20-eV to 50,000-eV electron beams in air and plastic Radiat. Res. 38 7-33
11. Connor E E, Mwamuka J, Gole A, Murphy C J and Wyatt M D 2005 Gold nanoparticles are taken up by human cells but do not cause acute cytotoxicity Small 1 325-7 (Pubitemid 43951781)
12. Farjo K M and Ma J X 2010 The potential of nanomedicine therapies to treat neovascular disease in the retina J. Angiogenes Res. 2 21
13. Fine S L and Maguire M G 2001 It is not time to abandon radiotherapy for neovascular age-related macular degeneration Arch. Ophthalmol. 119 275-6 (Pubitemid 32147938)
14. Garnica-Garza H M 2009 Contrast-enhanced radiotherapy: feasibility and characteristics of the physical absorbed dose distribution for deep-seated tumors Phys. Med. Biol. 54 5411-25
15. Gokeri G, Kocar C and Tombakoglu M 2010 Monte Carlo simulation of microbeam radiation therapy with an interlaced irradiation geometry and an Au contrast agent in a realistic head phantom Phys. Med. Biol. 55 7469-87
16. Hanlon J, Firpo M, Chell E, Moshfeghi D M and Bolch W E 2011 Stereotactic radiosurgery for AMD: a Monte Carlo-based assessment of patient-specific tissue doses Invest. Ophthalmol. Vis. Sci. 52 2334-42
17. Hanlon J, Lee C, Chell E, Gertner M, Hansen S, Howell R W and Bolch W E 2009 Kilovoltage stereotactic radiosurgery for age-related macular degeneration: assessment of optic nerve dose and patient effective dose Med. Phys. 36 3671-81
18. Iezzi R, Guru B R, Glybina I V, Mishra M K, Kennedy A and Kannan R M 2012 Dendrimer-based targeted intravitreal therapy for sustained attenuation of neuroinflammation in retinal degeneration Biomaterials 33 979-88
19. Jain S, Hirst D G and OSullivan J M 2012 Gold nanoparticles as novel agents for cancer therapy Br J. Radiol. 85 101-13
20. Kaiser P K 2010 Combination therapy with verteporfin and anti-VEGF agents in neovascular age-related macular degeneration: where do we stand Br. J. Ophthalmol. 94 143-5
21. Kang S J, Durairaj C, Kompella U B, OBrien J M and Grossniklaus H E 2009 Subconjunctival nanoparticle carboplatin in the treatment of murine retinoblastoma Arch. Ophthalmol. 127 1043-7
22. Kim J H, Kim K W, Kim M H and Yu Y S 2009 Intravenously administered gold nanoparticles pass through the blood-retinal barrier depending on the particle size, and induce no retinal toxicity Nanotechnology 20 505101
23. Lasagna-Reeves C, Gonzalez-Romero D, Barria M A, Olmedo I, Clos A, Sadagopa Ramanujam V M, Urayama A, Vergara L, Kogan M J and Soto C 2010 Bioaccumulation and toxicity of gold nanoparticles after repeated administration in mice Biochem. Biophys. Res. Commun. 393 649-55
24. Lechtman E, Chattopadhyay N, Cai Z, Mashouf S, Reilly R and Pignol J P 2011 Implications on clinical scenario of gold nanoparticle radiosensitization in regards to photon energy, nanoparticle size, concentration and location Phys. Med. Biol. 56 4631-47
25. McMahon S J et al 2011 Biological consequences of nanoscale energy deposition near irradiated heavy atom nanoparticles Sci. Rep. 1 18
26. Moshfeghi A A, Canton V M, Quiroz-Mercado H, Velez-Montoya R, Lopez-Miranda M J, Shusterman E M, Kaiser P K, Sanislo S R, Gertner M and Moshfeghi D M 2011a 16-Gy low-voltage x-ray irradiation followed by as-needed ranibizumab therapy for AMD: 6-month outcomes of a radiation-first strategy Ophthalmic Surg. Lasers Imaging 42 460-7
27. Moshfeghi D M, Kaiser P K and Gertner M 2011b Stereotactic low-voltage x-ray irradiation for age-related macular degeneration Br. J. Ophthalmol. 95 185-8
28. Mukherjee P, Bhattacharya R, Wang P, Wang L, Basu S, Nagy J A, Atala A, Mukhopadhyay D and Soker S 2005 Antiangiogenic properties of gold nanoparticles Clin. Cancer Res. 11 3530-4 (Pubitemid 40627908)
29. Murphy M J et al 2007 The management of imaging dose during image-guided radiotherapy: report of the AAPM Task Group 75 Med. Phys. 34 4041-63 (Pubitemid 47482906)
30. Ng E W and Adamis A P 2005 Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration Can. J. Ophthalmol. 40 352-68 (Pubitemid 40942262)
31. Ngwa W, Makrigiorgos G M and Berbeco R I 2010 Applying gold nanoparticles as tumor-vascular disrupting agents during brachytherapy: estimation of endothelial dose enhancement Phys. Med. Biol. 55 6533-48
32. Ngwa W, Makrigiorgos G M and Berbeco R I 2012 Gold nanoparticle-aided brachytherapy with vascular dose painting: estimation of dose enhancement to the tumor endothelial cell nucleus Med. Phys. 39 392-8
33. Ozkiris A 2010 Anti-VEGF agents for age-related macular degeneration Expert Opin. Ther. Pat. 20 103-18
34. Petrarca R and Jackson T L 2011 Radiation therapy for neovascular age-related macular degeneration Clin. Ophthalmol. 5 57-63
35. Poludniowski G, Landry G, DeBlois F, Evans P M and Verhaegen F 2009 SpekCalc: a program to calculate photon spectra from tungsten anode x-ray tubes Phys. Med. Biol. 54 N433-8
36. Raju H B, Hu Y, Vedula A, Dubovy S R and Goldberg J L 2011 Evaluation of magnetic micro- and nanoparticle toxicity to ocular tissues PLoS One 6 17452
37. Resnikoff S, Pascolini D, Etyaale D, Kocur I, Pararajasegaram R, Pokharel G P and Mariotti S P 2004 Global data on visual impairment in the year 2002 Bull. World Health Organ. 82 844-51 (Pubitemid 39573742)
38. Rosenfeld P J, Brown D M, Heier J S, Boyer D S, Kaiser P K, Chung C Y and Kim R Y 2006 Ranibizumab for neovascular age-related macular degeneration New Engl. J. Med. 355 1419-31 (Pubitemid 44511557)
39. Salehi-Had H, Roh M I, Giani A, Hisatomi T, Nakao S, Kim I K, Gragoudas E S, Vavvas D, Guccione S and Miller J W 2011 Utilizing targeted gene therapy with nanoparticles binding alpha v beta 3 for imaging and treating choroidal neovascularization PLoS One 6 18864
40. Shukla R, Bansal V, Chaudhary M, Basu A, Bhonde R R and Sastry M 2005 Biocompatibility of gold nanoparticles and their endocytotic fate inside the cellular compartment: a microscopic overview Langmuir 21 10644-54 (Pubitemid 41692144)
41. Silva R A, Moshfeghi A A, Kaiser P K, Singh R P and Moshfeghi D M 2011 Radiation treatment for age-related macular degeneration Semin. Ophthalmol. 26 121-30
42. Singh S R, Grossniklaus H E, Kang S J, Edelhauser H F, Ambati B K and Kompella U B 2009 Intravenous transferrin, RGD peptide and dual-targeted nanoparticles enhance anti-VEGF intraceptor gene delivery to laser-induced CNV Gene Ther. 16 645-59
43. Taddei P J, Chell E, Hansen S, Gertner M and Newhauser W D 2010 Assessment of targeting accuracy of a low-energy stereotactic radiosurgery treatment for age-related macular degeneration Phys. Med. Biol. 55 7037-54
44. Takeda A et al 2009 CCR3 is a target for age-related macular degeneration diagnosis and therapy Nature 460 225-30
45. Van den Heuvel F, Locquet J P and Nuyts S 2010 Beam energy considerations for gold nano-particle enhanced radiation treatment Phys. Med. Biol. 55 4509-20
46. Yip P P, Woo C F, Tang H H and Ho C K 2009 Triple therapy for neovascular age-related macular degeneration using single-session photodynamic therapy combined with intravitreal bevacizumab and triamcinolone Br. J. Ophthalmol. 93 754-8